Boston Scientific (NYSE:BSX) Issues FY 2025 Earnings Guidance

Key Points

• Boston Scientific has updated its FY 2025 earnings guidance, projecting EPS between 2.950 and 2.990 and revenue between $19.8 billion and $19.9 billion, exceeding consensus estimates.
• Analysts are optimistic, with the majority rating the stock as a "buy" and an average target price of $117.50.
• Insider trading reveals significant sells, with executives Joseph Michael Fitzgerald and Michael F. Mahoney selling large portions of their shares recently, reflecting a 10.02% and 21.90% decrease in their holdings, respectively.

Boston Scientific (NYSE:BSX - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 2.950-2.990 for the period, compared to the consensus EPS estimate of 2.918. The company issued revenue guidance of $19.8 billion-$19.9 billion, compared to the consensus revenue estimate of $19.5 billion.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. UBS Group boosted their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Leerink Partners assumed coverage on Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock. Evercore ISI boosted their price objective on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Finally, Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of "Buy" and an average target price of $117.50.

Boston Scientific Price Performance

BSX opened at $104.87 on Friday. The stock's 50-day moving average price is $103.61 and its 200 day moving average price is $101.80. Boston Scientific has a 12-month low of $71.88 and a 12-month high of $108.94. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. The firm has a market cap of $155.15 billion, a price-to-earnings ratio of 62.42, a PEG ratio of 2.57 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.39% and a net margin of 13.55%. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the business earned $0.62 EPS. Boston Scientific's revenue was up 22.8% on a year-over-year basis. As a group, sell-side analysts expect that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $106.97, for a total transaction of $5,348,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at $19,077,243.74. This represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $103.69, for a total value of $17,051,094.67. Following the sale, the chief executive officer owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 282,288 shares of company stock worth $29,411,601 over the last quarter. 0.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Boston Scientific

An institutional investor recently raised its position in Boston Scientific stock. Brighton Jones LLC grew its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 0.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 27,376 shares of the medical equipment provider's stock after acquiring an additional 226 shares during the quarter. Brighton Jones LLC's holdings in Boston Scientific were worth $2,445,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.